Rigel Pharmaceuticals (RIGL) Gains from Sales and Divestitures (2022 - 2025)
Rigel Pharmaceuticals' quarterly Gains from Sales and Divestitures came in at $143691.0 in Q3 2025, up 108.53% year-on-year from $68908.0 in Q3 2024, and little changed quarter-over-quarter from $143691.0 in Q2 2025.
Rigel Pharmaceuticals has reported Gains from Sales and Divestitures for 4 years, with the latest figure at $143691.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 143,691.00 |
| Sep 30, 2025 | 143,691.00 |
| Jun 30, 2025 | 143,691.00 |
| Jun 30, 2025 | 143,691.00 |
| Mar 31, 2025 | 125,783.00 |
| Mar 31, 2025 | 125,783.00 |
| Sep 30, 2024 | 68,908.00 |
| Sep 30, 2024 | 68,908.00 |
| Jun 30, 2024 | 66,408.00 |
| Jun 30, 2024 | 66,408.00 |
| Mar 31, 2024 | 489,992.00 |
| Mar 31, 2024 | 489,992.00 |
| Sep 30, 2023 | 435,006.00 |
| Sep 30, 2023 | 435,006.00 |
| Jun 30, 2023 | 435,006.00 |
| Jun 30, 2023 | 435,006.00 |
| Mar 31, 2023 | 266,256.00 |
| Mar 31, 2023 | 266,256.00 |
| Sep 30, 2022 | 203,750.00 |
| Sep 30, 2022 | 203,750.00 |
| Jun 30, 2022 | 203,750.00 |
| Jun 30, 2022 | 203,750.00 |
| Mar 31, 2022 | 22,500.00 |
| Mar 31, 2022 | 22,500.00 |